好兆头:中英新冠疫苗二期临床均产生中和抗体
图源:pixabay.com
撰文 | 计永胜
责编 | 汤佩兰
图1 ChAdOx1 nCoV-19组体液免疫应答水平。(图源:参考文献1)
图2 不同剂量组体液免疫应答水平。(图源:参考文献2)
[1]Pedro M Folegatti, Katie J Ewer, Parvinder K Aley, et al., (2020). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet, https://doi.org/10.1016/S0140-6736(20)31604-4
[2]Feng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, et al., (2020). Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, https://doi.org/10.1016/S0140-6736(20)31605-6
[3]Folegatti PM, Bittaye M, Flaxman A, et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viralvectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis 2020; 20: 816–26.
[4]Ugur Sahin, Alexander Muik, Evelyna Derhovanessian, et al., (2020). Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine. https://doi.org/10.1101/2020.07.17.20140533
[5]L.A. Jackson, E.J. Anderson, N.G. Rouphael, et al., (2020). An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. NEJM, DOI: 10.1056/NEJMoa2022483
制版编辑 | 皮皮鱼